Evolution of fibroblasts in the lung metastatic microenvironment is driven by stage-specific transcriptional plasticity

Abstract

Mortality from breast cancer is almost exclusively a result of tumor metastasis, and lungs are one of the main metastatic sites. Cancer-associated fibroblasts (CAFs) are prominent players in the microenvironment of breast cancer. However, their role in the metastatic niche is largely unknown. In this study, we profiled the transcriptional co-evolution of lung fibroblasts isolated from transgenic mice at defined stage-specific time points of metastases formation. Employing multiple knowledge-based platforms of data analysis provided powerful insights on functional and temporal regulation of the transcriptome of fibroblasts. We demonstrate that fibroblasts in lung metastases are transcriptionally dynamic and plastic, and reveal stage-specific gene signatures that imply functional tasks, including extracellular matrix remodeling, stress response and shaping the inflammatory microenvironment. Furthermore, we identified Myc as a central regulator of fibroblast rewiring and found that stromal upregulation of Myc transcriptional networks is associated with disease progression in human breast cancer.

Data availability

Sequencing data have been deposited in GEO under accession code GSE128999.

The following data sets were generated
The following previously published data sets were used

Article and author information

Author details

  1. Ophir Shani

    Pathology, Tel Aviv University, Tel Aviv, Israel
    Competing interests
    The authors declare that no competing interests exist.
  2. Yael Raz

    Pathology, Tel Aviv University, Tel Aviv, Israel
    Competing interests
    The authors declare that no competing interests exist.
  3. Lea Monteran

    Pathology, Tel Aviv University, Tel Aviv, Israel
    Competing interests
    The authors declare that no competing interests exist.
  4. Ye'ela Scharff

    Pathology, Tel Aviv University, Tel Aviv, Israel
    Competing interests
    The authors declare that no competing interests exist.
  5. Oshrat Levi-Galibov

    Biomolecular Sciences, The Weizmann Institute of Science, Rehovot, Israel
    Competing interests
    The authors declare that no competing interests exist.
  6. Or Megides

    Clinical Microbiology and Immunology, Tel Aviv University, Tel Aviv, Israel
    Competing interests
    The authors declare that no competing interests exist.
  7. Hila Shacham

    Clinical Microbiology and Immunology, Tel Aviv University, Tel Aviv, Israel
    Competing interests
    The authors declare that no competing interests exist.
  8. Noam Cohen

    Pathology, Tel Aviv University, Tel Aviv, Israel
    Competing interests
    The authors declare that no competing interests exist.
  9. Dana Silverbush

    Blavatnik School of Computer Sciences, Tel Aviv University, Tel Aviv, Israel
    Competing interests
    The authors declare that no competing interests exist.
  10. Camilla Avivi

    Pathology, Sheba Medical Center, Ramat Gan, Israel
    Competing interests
    The authors declare that no competing interests exist.
  11. Roded Sharan

    Blavatnik School of Computer Science, Tel Aviv University, Tel Aviv, Israel
    Competing interests
    The authors declare that no competing interests exist.
  12. Asaf Madi

    Pathology, Tel Aviv University, Tel Aviv, Israel
    Competing interests
    The authors declare that no competing interests exist.
  13. Ruth Scherz-Shouval

    Biomolecular Sciences, The Weizmann Institute of Science, Rehovot, Israel
    Competing interests
    The authors declare that no competing interests exist.
  14. Iris Barshack

    Pathology, Sheba Medical Center, Ramat Gan, Israel
    Competing interests
    The authors declare that no competing interests exist.
  15. Ilan Tsarfaty

    Clinical Microbiology and Immunology, Tel Aviv University, Tel Aviv, Israel
    Competing interests
    The authors declare that no competing interests exist.
  16. Neta Erez

    Pathology, Tel Aviv University, Tel Aviv, Israel
    For correspondence
    Netaerez@tauex.tau.ac.il
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6506-9074

Funding

H2020 European Research Council (637069 MetCAF)

  • Ophir Shani
  • Yael Raz

Israel Science Foundation (1060/18)

  • Ophir Shani
  • Yael Raz
  • Noam Cohen
  • Neta Erez

The Emerson Collective

  • Ophir Shani
  • Lea Monteran
  • Neta Erez

Israel Cancer Association

  • Ophir Shani
  • Neta Erez

Israel Cancer Research Fund (Project Grant)

  • Ophir Shani
  • Yael Raz
  • Lea Monteran
  • Neta Erez

Breast Cancer Research Foundation

  • Or Megides
  • Ilan Tsarfaty

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Wilbert Zwart, Netherlands Cancer Institute, Netherlands

Ethics

Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the Tel Aviv University. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols #: 01-18-035, M-13-026, 01-17-024) of the Tel Aviv University.

Human subjects: Human patient samples were collected and processed at the Sheba Medical Center, Israel under an approved institutional review board (IRB) (3112-16).

Version history

  1. Received: July 6, 2020
  2. Accepted: June 24, 2021
  3. Accepted Manuscript published: June 25, 2021 (version 1)
  4. Version of Record published: July 5, 2021 (version 2)

Copyright

© 2021, Shani et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,724
    views
  • 540
    downloads
  • 20
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Ophir Shani
  2. Yael Raz
  3. Lea Monteran
  4. Ye'ela Scharff
  5. Oshrat Levi-Galibov
  6. Or Megides
  7. Hila Shacham
  8. Noam Cohen
  9. Dana Silverbush
  10. Camilla Avivi
  11. Roded Sharan
  12. Asaf Madi
  13. Ruth Scherz-Shouval
  14. Iris Barshack
  15. Ilan Tsarfaty
  16. Neta Erez
(2021)
Evolution of fibroblasts in the lung metastatic microenvironment is driven by stage-specific transcriptional plasticity
eLife 10:e60745.
https://doi.org/10.7554/eLife.60745

Share this article

https://doi.org/10.7554/eLife.60745

Further reading

    1. Cancer Biology
    2. Cell Biology
    Stefanie Schmieder
    Insight

    Mutations in the gene for β-catenin cause liver cancer cells to release fewer exosomes, which reduces the number of immune cells infiltrating the tumor.

    1. Cancer Biology
    2. Cell Biology
    Dongyue Jiao, Huiru Sun ... Kun Gao
    Research Article

    Enhanced protein synthesis is a crucial molecular mechanism that allows cancer cells to survive, proliferate, metastasize, and develop resistance to anti-cancer treatments, and often arises as a consequence of increased signaling flux channeled to mRNA-bearing eukaryotic initiation factor 4F (eIF4F). However, the post-translational regulation of eIF4A1, an ATP-dependent RNA helicase and subunit of the eIF4F complex, is still poorly understood. Here, we demonstrate that IBTK, a substrate-binding adaptor of the Cullin 3-RING ubiquitin ligase (CRL3) complex, interacts with eIF4A1. The non-degradative ubiquitination of eIF4A1 catalyzed by the CRL3IBTK complex promotes cap-dependent translational initiation, nascent protein synthesis, oncogene expression, and cervical tumor cell growth both in vivo and in vitro. Moreover, we show that mTORC1 and S6K1, two key regulators of protein synthesis, directly phosphorylate IBTK to augment eIF4A1 ubiquitination and sustained oncogenic translation. This link between the CRL3IBTK complex and the mTORC1/S6K1 signaling pathway, which is frequently dysregulated in cancer, represents a promising target for anti-cancer therapies.